TickerFacts.

Pelthos Therapeutics Inc. (PTHS): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$22.69M
Year ended 2025-12-31
2024-12-31: -$5.79M2025-12-31: -$22.69M-$22.69M
2024-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$22.69Mn/m2026-03-19, From 2025-01-01
2024-12-31-$5.79Mn/a2026-03-19, From 2024-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Pelthos Therapeutics Inc. (PTHS)2025-12-31-$22.69Mn/m
Relay Therapeutics, Inc. (RLAY)2025-12-31-$235.87Mn/m
LENZ Therapeutics, Inc. (LENZ)2025-12-31-$70.00Mn/m
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31-$19.44Mn/m
Alector, Inc. (ALEC)2025-12-31-$184.07Mn/m
Metagenomi Therapeutics, Inc. (MGX)2025-12-31-$89.47Mn/m
Caribou Biosciences, Inc. (CRBU)2025-12-31-$112.35Mn/m
TScan Therapeutics, Inc. (TCRX)2025-12-31-$139.73Mn/m
Alpha Cognition Inc. (ACOG)2025-12-31-$20.67Mn/m

Compare PTHS, RLAY, LENZ, LCTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗